Clinical Study

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Zimple Kurlawala¹ and Vatsalya Vatsalya¹²

¹University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA
²Robley Rex VA Medical Center, Louisville, KY, USA

Correspondence should be addressed to Vatsalya Vatsalya; v0vats01@exchange.louisville.edu

Received 30 April 2016; Revised 28 August 2016; Accepted 5 October 2016

Academic Editor: Ildiko Racz

Copyright © 2016 Z. Kurlawala and V. Vatsalya. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia. Patients with clinically significant depression (high MADRS) reported a significant increase in akathisia measures at 6W which eventually decreased at 12W to below baseline levels. The increase in akathisia at 6W corresponded with a significant increase in the patients’ total drinks and heavy drinking pattern. Treatment with Quetiapine progressively lowered the occurrence of akathisia in alcohol dependent patients who do not show symptoms of depression. Quetiapine treatment lowered akathisia over time in heavy drinkers who had clinically significant symptoms of depression.

1. Introduction

Alcohol dependence is a major public health concern worldwide. Excessive consumption of alcohol over a prolonged period can have adverse neurocognitive effects [1]. Moderate alcohol consumption can transiently improve movement-associated symptoms such as essential tremors [2], dystonias [3, 4], and tics [5]. However, chronic alcohol consumption can trigger or aggravate hyperkinetic conditions such as akathisia, chorea, and myoclonus [6, 7]. Delirium tremens is a severe form of alcohol withdrawal with symptoms of tremors, restlessness, agitation, and altered mental function, peaking around 72 hours after the last drink [8].

The FDA has approved Quetiapine (Seroquel®) for the treatment of schizophrenia, bipolar disorder, and depression. Most clinical trials conducted so far have shown efficacy of Quetiapine to alleviate symptoms of depression, anxiety, and insomnia [9,10]. Additionally, Quetiapine improved symptoms of akathisia, dyskinesia, and other preexisting involuntary motor movements when used in clinical trials for treating psychotic syndromes, dementia, and Parkinson's disease [11–13]. When compared to Risperidone and Olanzapine in treatment of Parkinson's disease with or without dementia, Quetiapine treatment was just as effective and additionally did not worsen patients' motor symptoms [14]. Compared to a typical antipsychotic such as Chlorpromazine, Quetiapine treated patients showed lower incidence of Parkinsonian symptoms (32% versus 5%) [15].

Patients with concomitant alcohol dependence and depression share a common underlying molecular neuropathology and therefore have similar clinical phenotypic presentation [16]. Alcohol abuse [17, 18] and clinical depression have been individually associated with movement disorders such as akathisia. Fornazzari and Carlen reported development of akathisia in patients during alcohol withdrawal [19]. A large study by Baynes et al. involving 120 subjects reported
Table 1: Baseline demographics, drinking history markers, and acute withdrawal assessment in alcohol dependent patients by MADRS group and gender.

| Treatment and measures | Low MADRS (clinically nonsignificant) | High MADRS (clinically significant) | Significance between the MADRS grs. (p < 0.05) |
|------------------------|----------------------------------------|-------------------------------------|-----------------------------------------------|
|                        | Males (63)                               | Females (14)                        | Overall (77)                                  |
| Age (yrs.)             | 44.4 ± 10.0                              | 49.9 ± 8.5                          | 45.43 ± 9.99                                 |
| Weight (lb.)           | 194.9 ± 40.8                             | 153.2 ± 27.6                        | 187.34 ± 41.8                                |

**Drinking history**

|                | TD90 1268.9 ± 503.5 | AvgDPD90 14.1 ± 5.6 | HDD90 63.1 ± 22.7 | NDD90 80.5 ± 15.1 |
|----------------|---------------------|--------------------|-------------------|-------------------|
| CIWA BL        | 1.7 ± 2.0           | 1.1 ± 2.4          | 1.6 ± 2.1         | 1.1 ± 1.4         |
| CIWA 6 W       | 0.9 ± 1.3           | 0.6 ± 1.2          | 0.9 ± 1.2         | 0.9 ± 1.4         |
| CIWA 12 W      | 1.1 ± 1.4           | 0.1 ± 0.3          | 1.1 ± 1.4         | 1.7 ± 0.6         |

**Acute withdrawal assessment**

- CIWA: Clinical Institute Withdrawal Assessment of Alcohol.
- TD90: total drinks in 90 days; AvgDPD90: average drinks per drinking day in last 90 days; HDD90: heavy drinking days in last 90 days; NDD90: number of drinking days in last 90 days.

An association approaching significance \( p = 0.007 \) between depression measures and development of akathisia [20]. However, treatment of akathisia in the heavy drinking population with clinically significant depression remains an understudied area. This gap in our knowledge could limit our ability to treat movement disorders in alcoholics who are likely to have symptoms of depression. Using the global assessment item of the BARS scale, Quetiapine was associated with a statistically significant lowering of akathisia [15]. Thus, we aimed to investigate if Quetiapine reduced akathisia in alcohol dependent patients. We also studied effects of history of drinking and active drinking during the treatment course of Quetiapine XR.

2. Patients and Methods

2.1. Study Participant Population. This study is one of the investigational arms of a larger protocol (ClinicalTrials.gov: NCT#00498628) that was supported by National Institute on Alcohol Abuse and Alcoholism. This investigation evaluated the efficacy of Quetiapine XR in reducing akathisia in alcohol dependent patients with high and low depression scores. A total of 108 men and women received the treatment (Table 1).

The inclusion criteria used in this study were diagnosis of alcohol dependence (using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and age between 18 and 64 years. Men consumed 10 or more drinks per day while women consumed 8 or more drinks per day for at least 40% of the last 60 days of the 90-day drinking assessment (Timeline Followback, TLFB), and all subjects had 0.00 breath alcohol level at the time of consent. Major exclusions included other psychoactive drug dependence within the last year, positive urine screen for drugs, participation in other pharmacological/behavioral studies within the last three months, lifetime diagnosis of major depression or eating disorder, use of antidepressants (last 30 days) and/or antipsychotics (last 14 days) before randomization, and a score ≥10 on the Clinical Institute Withdrawal Assessment of Alcohol.

2.2. Procedures and Assessments. Study participants received Quetiapine XR (Seroquel XR® AstraZeneca, Wilmington, DE) for three months in 50 and 200 mg tablets [21]. Clinical and subjective assessments from baseline (0 W), week six (6 W), and end of week 12 (or during week 13, 12 W) were evaluated. The dose of the medication was titrated in the first two weeks up to a target dose of 400 mg/d, which continued through week 12 followed by one week of tapering dose. All individuals received medical management (MM) that included assessment of medication side effects, participant education, and advice on drinking [22].

2.3. Data Collection, Statistical Paradigm, and Analysis. Individual demographics were collected including age (years), sex (male or female), weight (lbs.), and drinking (TLFB) history. Age, weight, and recent drinking were included as covariates as needed. We used the following recent TLFB measures [23]: total drinks (TD90); average drinks per drinking day in last 90 days (AvgDPD90); number of drinking days in last 90 days (NDD90); and heavy drinking days in last 90 days (HDD90). Further, there was a 1-month period during the recruitment phase when similar drinking history measures were also collected for 30 days (TD30, HDD30, NDD30, and AvgDPD30). Six-week and twelve-week assessment of drinking history were collected using TLFB for the 2-week interval prior to the visit.

Patients were categorized by their MADRS scores at baseline (high MADRS or clinically significant if > seven; and low MADRS or clinically nonsignificant level if ≤ seven) [24]. The presence of clinically significant MADRS scores was used as the primary independent variable. We compared the prevalence of akathisia as the primary study outcome in patients with clinically significant and clinically non-significant depression and used the Barnes Akathisia Rating...
3. Results and Discussion

3.1. Characterization of Patients and Drinking History. Out of 108 enrolled patients, 31 patients showed clinically significant level of depression using the MADRS scale. Demographic measures were comparatively similar in all subgroups differentiated by MADRS group (Table 1). Patients consuming at least 10 drinks per day matched the profile of very heavy drinkers [26]. There were more males and they weighed more than females in both MADRS groups. There was no significant main effect of any of the demographic or drinking history markers between the two MADRS groups, and these patients also roughly matched in age and drinking history. We found that Quetiapine reduced the occurrence of akathisia in very heavy drinking patient population in the group having clinically significant depression (high MADRS scores). CIWA scores for the assessment of alcohol withdrawal severity did not show any clinical significance throughout the study period (Table 1). At baseline, there was a statistically significant elevation of CIWA scores found in patients with high MADRS; however numerically this elevation was not clinically significant.

3.2. Prevalence and Characterization of the Akathisia Measures. We performed repeated analysis of variance to measure severity of akathisia using BARS assessment at week 6 and week 12 comparing from baseline values to identify if there is any significant contrast existing between the timelines due to MADRS reporting. We found that there was a significant contrast of time, \( p \leq 0.001 \). This finding supports our assessment that time course of treatment has a significant effect on improvement of akathisia, demonstrated by gradual lowering of extent of reporting of akathisia in both MADRS groups. Notably, there was also a trending level of contrast effect in time and MADRS severity for akathisia reporting, \( p = 0.105 \). This suggested that Quetiapine was actively reducing akathisia symptoms in both groups. However, there was a trending difference between the two groups, for which assessment of prevalence of akathisia at each time point was tested further. We performed Chi-square analysis to separate this effect of Quetiapine treatment on occurrence of akathisia between the two groups. Also, there was no change in the significance observed when drinking history markers were included. Other studies that have studied the efficacy of Propranolol [27] and Lorazepam [28] for treatment of akathisia have also reported time-course dependent alleviation of akathisia symptoms. There is substantial evidence that 5-HT2A antagonists are successful in treating akathisia symptoms, exclusively neuroleptic-induced akathisia [29]. A part of the subject population in this study reported symptoms of akathisia from alcohol withdrawal regardless of baseline level of MADRS. Our data suggest that continued treatment with Quetiapine XR improved symptoms of akathisia especially in patients with clinically significant depression (high MADRS), when there was simultaneous lowering of alcohol intake.

Thereafter, we conducted Chi-square tests to evaluate significance of occurrence of akathisia during Quetiapine treatment course by depression level (Table 2). At baseline, patients in both MADRS groups experienced akathisia symptoms; however, there were no significant differences between the two groups. The occurrence of akathisia more than doubled at 6W from baseline reporting (0W) in the high MADRS group. Interestingly, akathisia incidence (44.4%)
Figure 1: Level of drinking in alcohol dependent patients by MADRS group and reporting of akathisia. (a) Baseline total drinks (TD30) by MADRS and akathisia. (b) Total drinks (TD weeks 4–6) at week 6 by MADRS and akathisia. (c) Total drinks (TD weeks 10–12) at week 12 by MADRS and akathisia. Data presented as M ± SE (mean with standard error). Significance was set at $p \leq 0.05$.

in high MADRS group at week 6 was also four times higher than the corresponding occurrence of akathisia in low MADRS group (Table 2). Our data are consistent with a recently published study, investigating efficacy of Quetiapine in treating alcohol dependence in patients diagnosed with bipolar disorder. The authors found that although Quetiapine treatment did not yield anticipated lowering of alcohol intake, patients experienced an increase in akathisia symptoms at 6 weeks (BARS score, $p = 0.04$), but not at 12 weeks [30]. At baseline, the likelihood of akathisia incidence in high MADRS group compared to low MADRS group was low. However, at week 6, this likelihood increased to significant moderate levels of occurrence in the same comparison that was also statistically significant (Table 2). At baseline and at 12 W, the likelihood ratio between the two groups remained low, tested by Chi-square analyses. At 12 weeks, the incidence of akathisia in high MADRS group dropped to 9%, a ∼5-fold decrease from 6 W and 2-fold decrease from baseline. Patients, who exhibited lowering of akathisia scores after 6 weeks of treatment, also had correspondingly lowered MADRS scores. This finding could be explained by the lowered levels of the heavy drinking markers (Figure 1(c)).

In the low MADRS group, the occurrence of akathisia continuously dropped during the entire treatment course with a 5-fold lowering at 12 W from the baseline occurrence (0 W), which also supports the role of Quetiapine in reducing akathisia in heavy drinking alcoholic patients without any ongoing clinically significant depression, who were actively drinking. Thus, the primary aim of this study was to determine if Quetiapine XR reduces akathisia in alcohol dependent patients. We found that it did in both depression groups. Akathisia is generally associated with the sense of inner restlessness, mental uneasiness, unrest, or dysphonia, which can be intense [31]. The occurrence and reduction in akathisia have also been evaluated in several studies that have used atypical antipsychotics including Clozapine [22], Olanzapine [23], Quetiapine [24–26], Ziprasidone [27], and others.

Based on our findings, we also report that there was an increase in akathisia in high MADRS group at 6 weeks of
treatment, and it was important to identify the cause for such an increase. Akathisia has also been reported to be either primary or secondary to drug use [28, 29]. It is known that alterations in movement can be provoked by alcohol intake [32]. We found an increase in akathisia reported at 6 weeks and evaluated recent drinking amount and drinking pattern at baseline, 6 W, and 12 W time points to identify whether this increase was due to a direct adverse effect of Quetiapine treatment, a change in drinking pattern, or interaction of Quetiapine with drinking in the high MADRS group.

Total drinks (marker of heavy drinking) recorded at all time points were higher in patients who exhibited akathisia in the high MADRS group. We did not find any significant differences in drinking either at baseline (0 W) or at the end of the study (12 W) between patients that exhibited akathisia and those that did not (Figures 1(a) and 1(c)). However, at 6 weeks of treatment, total drinks reported were approximately four times more in patients who exhibited akathisia symptoms in the high MADRS group (Figure 1(b)) and were highly statistically significant. The amount of drinking potentially influenced the incidence of akathisia at 6 W in high MADRS group. A sizeable proportion of patients with depression and related disease conditions reported higher susceptibility to heavy alcohol drinking [33]. Interestingly, in the patient group with low MADRS scores, total drinks decreased over time, and patients who exhibited akathisia did not show significant differences in total drinks compared to those who did not have akathisia, asserting the role of drinking and clinically relevant level of MADRS in the appearance of akathisia symptoms at 6 weeks in the high MADRS group.

Heavy drinking days (another marker of heavy drinking from TLFB questionnaire, HDD30) at baseline were higher in patients with akathisia in the high MADRS group. However, they were higher at both 6-week and 12-week assessments (Figures 2(a) and 2(c)). HDD at 6 weeks showed a significant elevation in patients who exhibited akathisia (Figure 2(b)) compared to those who did not, within the high MADRS group. Within the low MADRS group, total number of heavy drinking days progressively lowered as treatment continued and frequency of heavy drinking days was similar in patients with akathisia compared to those without akathisia.

Both the amount and pattern of heavy drinking were influential in increasing the incidence of akathisia in the high MADRS group at six weeks. The amount and pattern of heavy drinking were important factors in the development of akathisia.
drinking were lower in this group both at baseline and at 12 weeks of treatment. On the other hand, in the low MADRS group, we did not find any significant increase in patterns of heavy drinking during treatment, and the occurrence of akathisia progressively decreased over time. Thus, we did not observe any influence of drinking alone or its interaction with Quetiapine in patients who did not have clinically significant symptoms of depression. No other markers of drinking showed any significant differences between the two groups. We did not find any interaction between MADRS groups and the presence of akathisia.

4. Conclusions

Quetiapine XR seemed to alleviate akathisia symptoms in very heavy drinking alcohol dependent (AD) patients who did not have clinically significant symptoms of depression. In alcohol dependent patients with clinically significant symptoms of depression, the effects of Quetiapine XR in reducing akathisia do not seem to begin until after the first six weeks of treatment. Increases in the amount and pattern of heavy drinking potentially played a significant role in exacerbation of akathisia symptoms in heavy drinking AD patients. However, with continued treatment of Quetiapine XR, AD patients showed a significant lowering of the incidence of akathisia. Results from the present study extend our understanding of the interplay between heavy drinking, presence of clinically significant symptoms of depression, and the efficacy of Quetiapine XR in alleviating symptoms of akathisia in very heavy drinking alcohol dependent patients. Akathisia has been reported to either worsen or emerge as a new symptom during alcohol withdrawal in chronic alcoholics [19]. Alcohol dependence is known to be a frequent comorbid condition in depressed patients [34]. Results from our study show that an antidepressant drug such as Quetiapine XR may reduce akathisia potentially resulting from alcohol withdrawal.

Abbreviations

Quetiapine XR: Quetiapine fumarate XR  
AD: Alcohol dependents  
MADRS: Montgomery-Asberg Depression Rating Scale  
BARS: Barnes Akathisia Rating Scale  
TLFB: Timeline Followback  
MM: Medical management  
Baseline: 0 W  
Steady state: 6 W  
Study endpoint: 12 W.

Competing Interests

All authors declare no conflict of interests.

Acknowledgments

This study was supported by the following Grant: NIAAA (NIH): CSP-1027 (Vatsalya Vatsalya). Ms. Marion McClain provided editorial support.

References

[1] S. Mukherjee, “Alcoholism and its effects on the central nervous system,” *Current Neurovascular Research*, vol. 10, no. 3, pp. 256–262, 2013.
[2] G. Mostile and J. Jankovic, “Alcohol in essential tremor and other movement disorders,” *Movement Disorders*, vol. 25, no. 14, pp. 2274–2284, 2010.
[3] W. Koller, D. Graner, and A. Mlcoch, “Essential voice tremor: treatment with propranolol,” *Neurology*, vol. 35, no. 1, pp. 106–108, 1985.
[4] A. F. Mubaidin, “Alcohol with xylocaine for treatment of eyelid dystonia,” *European Journal of Neurology*, vol. 7, no. 2, pp. 213–215, 2000.
[5] K. R. Muller-Vahl, H. Kolbe, and R. Dengler, “Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms,” *Nervenarzt*, vol. 68, no. 12, pp. 985–989, 1997.
[6] M. Demirkiran and J. Jankovic, “Paroxysmal dyskinesias: clinical features and classification,” *Annals of Neurology*, vol. 38, no. 4, pp. 571–579, 1995.
[7] M. K. Bruno, H.-Y. Lee, G. W. J. Auburger et al., “Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia,” *Neurology*, vol. 68, no. 21, pp. 1782–1789, 2007.
[8] T. R. Kosten and P. G. O’Connor, “Management of drug and alcohol withdrawal,” *New England Journal of Medicine*, vol. 348, no. 18, pp. 1786–1795, 2003.
[9] S. P. Sattar, S. C. Bhatia, and F. Petty, “Potential benefits of quetiapine in the treatment of substance dependence disorders,” *Journal of Psychiatry and Neuroscience*, vol. 29, no. 6, pp. 452–457, 2004.
[10] E. P. Monnelly, D. A. Ciraulo, C. Knapp, J. LoCastro, and I. Sepulveda, “Quetiapine for treatment of alcohol dependence,” *Journal of Clinical Psychopharmacology*, vol. 24, no. 5, pp. 332–335, 2004.
[11] W. M. Glazer, “Review of incidence studies of tardive dyskinesia associated with typical antipsychotics,” *Journal of Clinical Psychiatry*, vol. 61, supplement 4, pp. 15–20, 2000.
[12] P. Shotbolt, M. Samuel, and A. David, “Quetiapine in the treatment of psychosis in Parkinson’s disease,” *Therapeutic Advances in Neurological Disorders*, vol. 3, no. 6, pp. 339–350, 2010.
[13] S. G. Potkin, G. M. Gharabawi, A. J. Greenspan et al., “A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization,” *Schizophrenia Research*, vol. 85, no. 1–3, pp. 254–265, 2006.
[14] S. Reddy, S. A. Factor, E. S. Molho, and P. J. Feustel, “The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia,” *Movement Disorders*, vol. 17, no. 4, pp. 676–681, 2002.
[15] J. Peuskens and C. G. G. Link, “A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia,” *Acta Psychiatrica Scandinavica*, vol. 96, no. 4, pp. 265–273, 1997.
[16] M. J. Gandal and D. H. Geschwind, “The genetics-driven revival in neuropsychiatric drug development,” *Biological Psychiatry*, vol. 79, no. 8, pp. 628–630, 2016.
[17] E. G. Lutz, “Neuroleptic induced akathisia and dystonia triggered by alcohol,” *Journal of the American Medical Association*, vol. 236, no. 21, pp. 2422–2423, 1976.
[18] J. Neiman, A. E. Lang, L. Fomazzari, and P. L. Carlen, “Movement disorders in alcoholism: a review,” *Neurology*, vol. 40, no. 5, pp. 741–746, 1990.
[19] L. Fornazzari and P. L. Carlen, “Transient choreiform dyskinesias during alcohol withdrawal,” *Canadian Journal of Neurological Sciences*, vol. 9, no. 2, pp. 89–90, 1982.

[20] D. Baynes, C. Mulholland, S. J. Cooper et al., “Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment,” *Schizophrenia Research*, vol. 45, no. 1-2, pp. 47–56, 2000.

[21] R. Z. Litten, J. B. Fertig, D. E. Falk et al., "A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate xr in very heavy-drinking alcohol-dependent patients," *Alcoholism: Clinical and Experimental Research*, vol. 36, no. 3, pp. 406–416, 2012.

[22] H. M. Pettinati and S. O’Malley, "Predictors of response in treating alcohol dependence," *Alcoholism-Clinical and Experimental Research*, vol. 28, no. 5, p. 184a, 2004.

[23] L. C. Sobell, S. Agrawal, M. B. Sobell et al., "Comparison of a quick drinking screen with the timeline followback for individuals with alcohol problems," *Journal of Studies on Alcohol*, vol. 64, no. 6, pp. 858–861, 2003.

[24] S. A. Montgomery and M. Asberg, "A new depression scale designed to be sensitive to change," *British Journal of Psychiatry*, vol. 134, no. 4, pp. 382–389, 1979.

[25] T. R. E. Barnes, "The barnes akathisia rating scale—revisited;" *Journal of Psychopharmacology*, vol. 17, no. 4, pp. 365–370, 2003.

[26] D. J. Pilowsky and L. T. Wu, "Screening for alcohol and drug use disorders among adults in primary care: a review," *Journal of Substance Abuse and Rehabilitation*, vol. 3, no. 1, pp. 25–34, 2012.

[27] J. E. Lipmski Jr. and G. S. Zubenko, "Propranolol in the treatment of neuroleptic-induced akathisia," *The American Journal of Psychiatry*, vol. 141, no. 3, pp. 412–415, 1984.

[28] M. Bartels, K. Heide, K. Mann, and H. W. Schied, "Treatment of akathisia with lorazepam. An open clinical trial," *Pharmacopsychiatry*, vol. 20, no. 2, pp. 51–53, 1987.

[29] Z. G. Laoutidis and C. Luckhaus, "5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis," *International Journal of Neuropsychopharmacology*, vol. 17, no. 5, pp. 823–832, 2014.

[30] E. S. Brown, D. Davila, A. Nakamura et al., "A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence," *Alcoholism: Clinical and Experimental Research*, vol. 38, no. 7, pp. 2113–2118, 2014.

[31] T. R. E. Barnes, "A rating scale for drug-induced akathisia," *British Journal of Psychiatry*, vol. 154, pp. 672–676, 1989.

[32] P. L. Carlen, M. A. Lee, M. Jacob, and O. Livshits, "Parkinsonism provoked by alcoholism," *Annals of Neurology*, vol. 9, no. 1, pp. 84–86, 1981.

[33] Q. Fu, A. C. Heath, K. K. Bucholz et al., "Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men," *Archives of General Psychiatry*, vol. 59, no. 12, pp. 1125–1132, 2002.

[34] J. M. Boden and D. M. Fergusson, "Alcohol and depression," *Addiction*, vol. 106, no. 5, pp. 906–914, 2011.